the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection

NCT04893694 | Completed

• 1 other identifier: Oral SARS 2
• Study Type: observational
• Target: 385
• Locations: 1 country
• Sites: 1

Brief Summary

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection

Conditions

SARS-CoV2 Infection

Keywords

SARS-CoV2; Oral Manifestation; prevalence

Outcome Measures

Primary Outcomes (1)

• Oral Manifestation

  presence or absence of Oral Manifestation in SARS-CO2

  one week

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

This is a multicenter cross- sectional study to study the prevalence of oral manifestation among patients with SARS-CoV2 infection and identify the range of the oral manifestation and site of lesions

You may qualify if:

• A diagnosis of SARS-CoV2 with PCR.
• Age range from 18-60 years old
• Hospital admission not more than 10 days

You may not qualify if:

• Pregnancy or contraceptive pills
• Lactation
• Any auto-immune disease that could affect the oral mucosa
• On any neoplastic therapy.
• Uncontrolled diabetes.

Sponsors & Collaborators

• Fayoum University: lead
• Ministry of Health and Population, Egypt: collaborator

Study Sites (1)

Faculty of Dentistry

Al Fayyum, 63514, Egypt

Location

Related Publications (3)

• Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x.

  PMID: 32094336 BACKGROUND

• Dziedzic A, Wojtyczka R. The impact of coronavirus infectious disease 19 (COVID-19) on oral health. Oral Dis. 2021 Apr;27 Suppl 3(Suppl 3):703-706. doi: 10.1111/odi.13359. Epub 2020 May 6.

  PMID: 32304276 BACKGROUND

• Riad A, Klugar M, Krsek M. COVID-19-Related Oral Manifestations: Early Disease Features? Oral Dis. 2022 Apr;28 Suppl 1(Suppl 1):940-942. doi: 10.1111/odi.13516. Epub 2020 Jul 16. No abstract available.

  PMID: 32603497 BACKGROUND

MeSH Terms

Conditions

COVID-19; Oral Manifestations

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Mouth Diseases; Stomatognathic Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: associate professor in oral & maxillofacial Surgery Department

Study Record Dates

• First Submitted: May 15, 2021
• First Posted: May 19, 2021
• Study Start: May 20, 2021
• Primary Completion: June 20, 2021
• Study Completion: July 15, 2021
• Last Updated: August 24, 2021

Record last verified: 2021-08

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)